study of the effectiveness of SALIRAVIRA as a natural product on the treatment of COVID-19 patients
Not Applicable
- Conditions
- COVID-19.COVID-19 virus identifiedU07.1
- Registration Number
- IRCT20201220049771N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Clinical confirmation of coronavirus infection
COVID-19 positive test reporting by RT-PCR
Cases with contact history with a COVID-19 patients in last 10 days
Lung involvement below 20% - Using CT-Scan
Exclusion Criteria
Pregnancy and Lactation cases
Cases with malignant tumors and other acute systemic diseases or special indication
Patients suffering from autoimmune diseases like Psoriasis, ALS and MS
Patients with comorbidity of respiratory life-threatening problems
Addiction to drugs and alcohol
Participation to another clinical trial for COVID-19
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viral Clearance. Timepoint: At the beginning of the study and and 4, 8 days after intake. Method of measurement: Polymerase chain reaction (PCR).;Fever and symptoms. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Using a thermometer and clinical diagnosis.;Shortness of breath. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Medical diagnosis.
- Secondary Outcome Measures
Name Time Method Olfactory (sense of smell). Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Questionnaire with interview.;Sense of taste. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Questionnaire with interview.